درباره این اپیزود
Over the last several years, gene therapy for hemophilia B has become a reality. Some received it through clinical trials, and others received it after marketing authorizations and reimbursement approvals in their countries. Each of them had a difficult, life-changing decision to make. They needed to fully understand the potential benefits and risks, and the physicians responsible for their treatment needed to be assured that they were providing fully informed consent to the therapy. This process is called shared decision-making. In this episode of our second podcast series, GENE THERAPY FOR HEMOPHILIA – FROM DREAM TO REALITY, four people, two physicians and two people with hemophilia, were invited to share their insight on this topic.
Host: Sarah Ford, CEO, Canadian Hemophilia Society
Guest Speakers: Dr Pratima Chowdary, U.K.; Dr Davide Matino, Canada; Brian O'Mahony, Ireland; David Page, Canada
This series is a creation of The Canadian Hemophilia Society - to find out more go to www.hemophilia.ca/gene-therapy
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
